The Prevalence of Antinuclear Antibodies in the General Population of China: A Cross-Sectional Study  by Guo, Ya-Ping et al.
Current Therapeutic Research 76 (2014) 116–119Contents lists available at ScienceDirectCurrent Therapeutic Researchhttp://d
0011-39
n Add
North G
E-m
† Thjournal homepage: www.elsevier.com/locate/cuthreThe Prevalence of Antinuclear Antibodies in the General Population of
China: A Cross-Sectional Study
Ya-Ping Guo, BS1,†, Chun-Guang Wang, MD1,†, Xin Liu, MSc1, Yi-Qian Huang, BS1,
De-Li Guo, BS1, Xing-Zhuo Jing, BS2, Chun-Gang Yuan, PhD3, Song Yang, BS1,
Jin-Mei Liu, BS1, Meng-Si Han, BS1, Hong-Xing Li, PhD1,n
1 The First Center Hospital of Bao Ding, Baoding, Hebei, China
2 The Fifth Hospital of Baoding, Baoding, Hebei, China
3 School of Environmental Science and Engineering, North China Electric Power University, Baoding, Hebei, Chinaa r t i c l e i n f o
Article history:
Accepted 26 June 2014
Background: The incidence of autoimmune diseases such as systemic lupus erythematosus, rheumatoid
arthritis, and primary biliary cirrhosis has increased signiﬁcantly in China. Information about theKey words:
antinuclear antibody
autoimmune diseases
Chinese
prevalencex.doi.org/10.1016/j.curtheres.2014.06.004
3X/& 2014. The Authors. Published by Elsevier
ress correspondence to: Hong-Xing Li, The Firs
reat Wall St 320, Baoding, Hebei 071000 Chin
ail address: bdsdyzxyyjyk@163.com (H.-X. Li)
ese authors contributed equally to this worka b s t r a c t
susceptibility or potential of autoimmune diseases in the general population is lacking.
Objective: To explore the prevalence of antinuclear antibody (ANA) and its speciﬁcities in the general
population in China.
Methods: Twenty thousand nine hundred seventy sera samples were taken from the physical examina-
tion center in Baoding, China. Indirect immunoﬂuorescence and line immunoassays were used to detect
ANA and its speciﬁcities, respectively.
Results: Samples from females had a higher prevalence of ANA than samples from males (χ2 ¼ 278.55;
P o 0.01). For both sexes, the prevalence of ANA positively correlated with age and there were signiﬁcant
differences among different age groups at 10-year intervals, except the 80 years group (P o 0.05). One
thousand two hundred forty-three ANA-positive samples were further analyzed with line immunoassays.
There was a signiﬁcant difference among age groups and between sex groups in terms of the speciﬁc
autoantibodies (P o 0.01). The autoantibodies with the top-3 positive frequencies were anti-Ro-52, anti-
M2, and anti-SSA.
Conclusions: There was a high prevalence of ANA positivity in the general Chinese population that
seemed to be inﬂuenced by sex and age and correlated with speciﬁc autoantibodies.
& 2014. The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
The incidence of autoimmune diseases (AIDs) such as systemic
lupus erythematosus (SLE), rheumatoid arthritis, and primary
biliary cirrhosis (PBC) has been increasing in China.1,2 Until now,
the antinuclear antibody (ANA) test, wherein antibodies are
detected by indirect immunoﬂuorescence assay on HEp-2 cells, is
commonly used as an initial screening method. The presence of
ANA is nonspeciﬁc and can be associated with many nonautoim-
mune factors, such as carcinoma, infection, pharmaceuticals, and
environmental factors. As a result, an ANA positive frequency in
healthy individuals 420% has been reported.3 On the other hand,Inc. This is an open access article u
t Center Hospital of Bao Ding,
a.
.
.ANA may exist several years before an AID can be diagnosed,4 with
higher titer of ANA being correlated closely with a higher risk of
the onset of AIDs during adolescence and adulthood.5–8 The
epidemiologic characteristics of AID in different countries and
districts varies.9 To our knowledge, information about the ANA
prevalence and the susceptibility or potential of AIDs in the
general population of China is lacking. We aimed to evaluate the
ANA prevalence in a wide range of the general Chinese population
(aged 2–88 years).Materials and Methods
Study population
To assess the ANA positive rate among the general popu-
lation of China, we conducted a cross-sectional study. Twentynder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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examination center in Baoding, Hebei, China, from July 2011 to
September 2013 (Figure 1). The sample size and male to female
ratio conform to the standard of the sixth National Census
of China in 2010–2011 (http://www.stats.gov.cn/tjsj/pcsj/rkpc/
6rp/indexch.htm). A total of 6800 children (including 3300 girls
and 3200 boys) aged from 2 to 18 years were recruited from
3 public kindergartens, 5 middle schools, and 2 high schools. The
other participants consisted of 14,170 individuals (7220 women
and 6950 men) obtained by random sampling. Participants
with established AID were excluded from this study. Informed
consent was obtained from all participants. The study complied
with the World Medical Association Declaration of Helsinki
and was approved by the Ethics Committee of the First Center
Hospital of Bao Ding. All data were dealt with in an anonymous
way.Antibody assays
Sera were tested by indirect ﬂuorescence on HEp-2 cells
according to the manufacturer’s instructions (Euroimmun AG,
Lubeck, Germany). Titer Z1:320 was considered to be positive.
As a result, 243 positive samples were further tested by line
immunoassay (LIA) (Euroimmun AG) for 15 speciﬁc autoantibodies
(ie, anti-nRNP, anti-Sm, anti-SSA, anti-Ro52, anti-SSB, anti-Jo-1,
anti-Scl-70, anti-CNEPB, anti-dsDNA, anti-His, anti-PCNA, anti-
Nuk, anti-Rib, anti-M2, and anti-PMScl-70). The sera for LIA testAbout 60,000 potential su
annual physical examina
Examine Center in Baodin
subjects with established
autoimmune diseases excluded
6,800 children (aged from
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Figure 1. Flowchart for the involvement of potential participants in the study. ANA ¼ anwere diluted 1:100. EUROBlotMaster (Euroimmun AG) and EURO-
LineScan (Euroimmun AG) were used to complete the operation
and for test result interpretation, respectively.
Statistical analysis
SPSS for Windows version 17.0 (IBM-SPSS, Inc, Armonk, New
York) was used for statistical calculations. Nonparametric analysis
with the Wilcoxon signed-rank test was used for matched pairs.
Categorical variables were compared using χ2 test as appropriate.
P o 0.05 was considered to be statistically signiﬁcant.Results
The age and sex distribution of 20,970 participants are sum-
marized in Table I. The ages ranged from 2 to 88 years, with mean
age 32 (19.7) years for both sexes.
The prevalence of ANA in male and female participants by age
groups are shown in Table I. The overall prevalence of ANA was
5.92% and correlated positively with age. There were signiﬁcant
differences among each age group except age older than 80 years, as
shown in Table I (P o 0.01). In the female group, there are 2 sharp
peaks in ANA positivity at the 20-year and 40-year age groups.
In 1243 ANA-positive sera tested by LIA, 44.2% were positive for
at least 1 of 15 speciﬁc ANA antibodies. In terms of the effect of
age and sex on ANA positivity, there were signiﬁcant differences
among the 3 groups (ie, r20 years, 21–49 years, and Z50 years;bjects involved in the
tion in the Physical
g during 2011–2013
subjects without undertaking
IIF-ANA test excluded
 2 to 18) from given
s inculded and
ubjects inculded
ive for ANA
 for specificities
d consent
tinuclear antibodies; IIF ¼ indirect immunoﬂuorescence; LIA ¼ line immunoassay.
Table I
Distribution of antinuclear antibody positive frequency in male and female
participants at different ages.
Age group, y
Positive/case numbers
χ2 P
Male Female
2–o10 21/1300 33/1200 25.96 o0.001
10–o20 55/2200 176/2150 12.74 o0.001
20–o30 39/1700 143/1680 64.12 o0.001
30–o40 48/1800 109/1840 23.40 o0.001
40–o50 49/1500 105/1480 22.27 o0.001
50–o60 43/1000 138/970 58.15 o0.001
60–o70 43/600 95/550 27.75 o0.001
70–o80 30/350 79/400 18.78 o0.001
80þ 12/100 25/150 1.04 0.365
Total 340/10,550 903/10,420 278.55 o0.001
Table III
Numbers of antinuclear antibody (ANA)-speciﬁc antibodies in positive sera, by sex.
ANA-speciﬁc antibody
Positive numbers
Frequency (%) χ2 P value
Male Female
Anti-nRNP 16 37 6.0 8.32 o0.01
Anti-Sm 10 24 4.0 0.67 0.41
Anti-SSA 30 93 14.3 32.27 o0.01
Anti-Ro52 40 123 19.0 42.26 o0.01
Anti-SSB 11 24 4.1 4.83 0.03
Anti-Jo-1 6 13 2.2 2.58 0.11
Anti-Scl-70 0 6 0.7 — —
Anti-CB 5 60 7.6 46.54 o0.01
Anti-dsDNA 8 33 4.8 15.24 o0.01
Anti-his 16 41 6.6 10.97 o0.01
Anti-PCNA 5 19 2.8 8.17 o0.01
Anti-Nuk 8 10 2.1 0.222 0.637
Anti-Rib 5 24 3.4 12.45 o0.01
Anti-M2 32 121 17.8 51.77 o0.01
Anti-PM 13 27 4.7 4.90 0.03
Total 205 655 100 236.47 o0.01
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236.47; P o 0.01), as shown in Table I and Table II, respectively.
The autoantibodies with the top-3 positive frequency were anti-
Ro-52 (19%), anti-M2 (17.8%), and anti-SSA (14.3%); whereas anti-
Scl-70, anti-Jo-1, and anti-Sm were the less frequently detected
antibodies among the autoantibodies detected (Table III).Discussion
This is the ﬁrst research into the prevalence of ANA in the
general Chinese population. Satoh et al9 hold that the ANA
prevalence in the US population of individuals aged 12 years and
older is 13.8%, and based on National Health and Nutrition
Examination Survey 1999-2004 data, more than 32 million people
in the United States are positive for ANA. Other studies indicate
that Japanese show a 9.5% prevalence at a 1:100 cutoff level
dilution,10 whereas for Indians it is 12.3%.11 Anti-Ro-52/SSA was
the most detected antibody in both of those studies.10,11 In the
present and another relevant study,12 Chinese showed a relatively
moderate frequency of 13.98% at 1:100 titers. Based on that
comparison among different nations, we hold the opinion that
ANA positive frequency in adults differs by geography. Sex and age
had been assumed to be the factors that inﬂuenced ANA positivity.
In our study, ANA prevalence correlated positively with age on the
whole, with higher prevalence present in the 20- to 30-year and
40- to 50-year groups. The latter peak is in line with the singleTable II
Numbers of antinuclear antibody (ANA)-speciﬁc antibodies in positive sera, by
age group.
ANA-speciﬁc antibody
Positive numbers
χ2 P
r20 y 21–49 y Z50 y
Anti-nRNP 13 14 25 5.12 0.08
Anti-Sm 6 8 17 5.35 0.07
Anti-SSA 21 40 67 28.24 o0.01
Anti-Ro52 25 43 98 55.96 o0.01
Anti-SSB 6 10 19 7.60 0.02
Anti-Jo-1 0 3 14 14.63 o0.01
Anti-Scl-70 0 3 3 – –
Anti-CB 5 22 38 22.84 o0.01
Anti-dsDNA 8 11 22 7.95 0.02
Anti-his 6 16 35 22.84 o0.01
Anti-PCNA 16 0 8 2.67 0.10
Anti-Nuk 0 6 11 0.89 0.35
Anti-Rib 2 8 19 15.38 o0.01
Anti-M2 25 17 112 109.90 o0.01
Anti-PM 6 8 24 12.95 o0.01
Total 139 209 512 275.04 o0.01peak at age 40 to 49 years described in a US population9 that was
characterized by the physiologic stage of puberty and menopause,
implying that estrogen may play an important role. As such, some
similarities of genetic deposition and hormone factors may have
an inﬂuence on disease manifestations.13 Between the sexes, our
results indicate that the female to male ratio in ANA positive
cohorts is almost 4:1, except in the 80 years group.
Our study also showed that ANA positivity in girls (8.2%) was
higher than in boys (2.5%). This indicated that females have a
higher ANA titer than males even at a relatively immature stage.
Because ANA-IIF is a primary screening test for adolescent SLE,14
this method maybe used routinely to screen for ANA-positivity in
younger people. Hayashi et al10 reported that it is important to
emphasize the ANA titer as a prognostic marker in certain AIDs,
and a 1:160 or 1:320 dilution titer is recommended. Although ANA
may be inﬂuenced by nonimmune factors, several articles show
that the positive frequency is no more than 5% at a dilution titer of
1:160 in the general population.10,15 In our study, at the cutoff
value of 1:320 titer, we found a similar result to previous studies in
that older people were prone to higher frequency of ANA positivity
than younger people (Figure 2).
Consistent with the ﬁndings in a Japanese population,4,10 we
found anti-Ro52/SSA was the most prevalent autoantibody in the
general population. Ro-52/SSA is a useful serologic marker for SLE
and Sjogren syndrome, myositis, systemic sclerosis, and PBC.15
Anti-Ro/SSA and antichromatin had the highest predictive value45.00%
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Figure 2. Frequency of the presence of antinuclear antibodies (ANA), by age group
and sex.
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reached 12.7%. The prevalence of patients with asymptomatic PBC
in an Asian population derived from previous studies18,19 seemed
to be larger than that inferred from our study. Coincident to the
data from Japanese residents,10 our results showed that anti-Scl-
70, anti-Jo-1, anti-Nuk, and anti-Sm were the least-detected
antibodies.
Certain limitations exist in our study. It is a pilot study on a large-
scale population without comprehensive consideration of other fac-
tors such as occupation, genetic deposition, and biochemical factors.Conclusions
ANA positive frequency is high in the general Chinese popula-
tion and differs in different sex and age groups.Acknowledgments
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